These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8602021)

  • 1. Intrahepatic cholestasis associated with moclobemide leading to death.
    Timmings P; Lamont D
    Lancet; 1996 Mar; 347(9003):762-3. PubMed ID: 8602021
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholestatic hepatitis associated with the use of moclobemide].
    García-Díaz JD; Gila A; Fraguas C; Castillo I
    Med Clin (Barc); 1998 Jun; 111(2):77. PubMed ID: 9706594
    [No Abstract]   [Full Text] [Related]  

  • 3. Antidepressant-associated fatal intrahepatic cholestasis.
    Dollow S
    Lancet; 1996 May; 347(9010):1268-9. PubMed ID: 8622488
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypertension with moclobemide.
    Laux G; Philipp M; Kohnen R
    Lancet; 1996 May; 347(9011):1330. PubMed ID: 8622520
    [No Abstract]   [Full Text] [Related]  

  • 5. Galactorrhoea with moclobemide.
    Dunn NR; Freemantle SN; Pearce GL; Mann RD
    Lancet; 1998 Mar; 351(9105):802. PubMed ID: 9519955
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe adverse reaction to moclobemide.
    O'Kane GM; Gottlieb T
    Lancet; 1996 May; 347(9011):1329-30. PubMed ID: 8622519
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypertension with moclobemide.
    Coulter DM; Pillans PI
    Lancet; 1995 Oct; 346(8981):1032. PubMed ID: 7475559
    [No Abstract]   [Full Text] [Related]  

  • 8. [Moclobemide (Aurorix). A new monoamine oxidase inhibitor not requiring dietary restrictions].
    Larsen JK
    Ugeskr Laeger; 1991 Feb; 153(6):449-52. PubMed ID: 2000658
    [No Abstract]   [Full Text] [Related]  

  • 9. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 10. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aurorix (moclomebide) is a second choice preparation--limit prescription].
    Lakartidningen; 1991 May; 88(21):2000-1. PubMed ID: 2056821
    [No Abstract]   [Full Text] [Related]  

  • 12. Depression in medical illness. Workshop report.
    Paykel E
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):205-7. PubMed ID: 8468445
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aurorix--an antidepressant with a wide spectrum of action].
    Iakovlev VA
    Voen Med Zh; 1998 Apr; 319(4):50-2. PubMed ID: 9633256
    [No Abstract]   [Full Text] [Related]  

  • 14. Moclobemide (Ro 11-1163) safety in depressed patients.
    Moll E; Hetzel W
    Acta Psychiatr Scand Suppl; 1990; 360():69-70. PubMed ID: 2248078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of moclobemide in clinical use.
    Chen DT; Ruch R
    Clin Neuropharmacol; 1993; 16 Suppl 2():S63-8. PubMed ID: 8313399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension with moclobemide.
    Boyd IW
    Lancet; 1995 Dec; 346(8988):1498. PubMed ID: 7491028
    [No Abstract]   [Full Text] [Related]  

  • 17. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR; Burrows GD
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral oedema associated with moclobemide.
    Alderman CP; Callary JA; Kent AL
    Med J Aust; 1992 Jul; 157(2):144. PubMed ID: 1630391
    [No Abstract]   [Full Text] [Related]  

  • 19. [Severe hyponatremia induced by moclobemide].
    Mercier S; Harry P; Merit JB; Gamelin L
    Therapie; 1997; 52(1):82-3. PubMed ID: 9183932
    [No Abstract]   [Full Text] [Related]  

  • 20. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
    Juruena MF; Pires ML; Calil HM
    Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.